This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231

APPLICATION NO./
CONTROL NO.

FILING DATE

FIRST NAMED INVENTOR /
PATENT IN REEXAMINATION

ATTORNEY DOCKET NO.



EXAMINER	

ART UNIT PAPER

1203

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 3.7 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne R. Kubelik whose telephone number is (703) 308-5059, which sometime in January will change to (571) 272-0801. The examiner can normally be reached on Monday through Friday, 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson, can be reached at (703) 308-4310. The fax number for the organization where this application or proceeding is assigned is (703) 306-3218.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vincinia 22313-1450

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/019,823 06/12/2002 Jonathan Griffin **SYN-128** 9917 7590 12/17/2003 EXAMINER Colleen Superko KUBELIK, ANNE R Hale & Dorr 60 State Street ART UNIT PAPER NUMBER Boston, MA: 02109 1638 DATE MAILED: 12/17/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

copy to Sel

HALE & DORR DOCKETING

RE: 09846.298 (5)

Action Date: 1100 Set 180

Action to be Taken: NOTE.

Ducksted By M. On: (2-22-05)

PTO-90C (Rev. 10/03)

•	2 2004 S			
		Application No.	Applicant(s)	
•	Notice to Comply	10/019,823	GRIFFIN ET AL.	
	Notice to Comply	Examiner	Art Unit	
		Anne R. Kubelik	1638	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e):
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1,822 and/or 1,823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☑ 7. Other: CRF DOES NOT MATCH APPLICATION SPECIFICATION

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

Technical Assistance......703-287-0200

To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



Syngenta
Patent and Trademark Dept.
3054 Cornwallis Road
Research Triangle Park,
North Carolina 27709-2257
Tel (919) 597-3031
Fax (919) 541-8689

22-Dec-03

ATTN: Michael Syngenta Lin Jealott's Hi			50431/PPDUSPCT
Centre			
Bracknell	B B A A		
GB-Berkshire	RG42 6YA		
DUE DATE:		RESPONSE DATE:	 7
January 17,	2004		
Re:	Application of GRI	FFIN ET AL.	_
	Case No. 50431/PPD	OUSPCT	
	Application No. 10	/019823	
Tadian and C			
Ladies and G	entiemen:		•
Enclosed are	copies of the foll	owing:	
Filing Phase			
Regular	Application filed a	s a Priority Applicat:	ion
		ed as a Priority Appl:	
		-	rovisional Application
] Regular			tion(s) and/or Foreign
Applicat			(·, ·····, ····
CPA Tran	smittal Form		
	tion of Application	No	
Division	of Application No.		
	= =	lication No.	
	PCT Application Int		
Official	Filing Receipt (Dat		
Other Doo			
rosecution 1	, , ,		
		PTO - Notice To Comply	(Due Date: January 17,
004)		is motification comply	(bue bate. bandary 17,
Paper(s)	sent to the PTO		
] Other Doc	cument(s)		
ssuance			
] Notice of	Allowance (Dated:)	
=	ification Form		
	three soft copies)		
iscellaneous Notice of	Abandonment (Dated	1:	
_		signment Document (Rec	ordation Date:
Other Doc		ragiment bocument (Rec	ordation Date:)

Very truly yours,

Oksana Buynitzky